![Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study - The Lancet Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study - The Lancet](https://www.thelancet.com/cms/attachment/2092108136/2076395957/gr1.gif)
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study - The Lancet
A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia | Haematologica
![Aggressive multiple sclerosis: proposed definition and treatment algorithm | Nature Reviews Neurology Aggressive multiple sclerosis: proposed definition and treatment algorithm | Nature Reviews Neurology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fnrneurol.2015.85/MediaObjects/41582_2015_Article_BFnrneurol201585_Fig1_HTML.jpg)
Aggressive multiple sclerosis: proposed definition and treatment algorithm | Nature Reviews Neurology
![Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors: Cell Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors: Cell](https://www.cell.com/cms/attachment/ac973c6f-0941-4dfb-a37d-8df7d7c6bb38/gr1_lrg.jpg)